Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling

Drug Metabolism and Disposition

Volumn 41, Issue 11, 2013, Pages 1967-1971

  Zamek Gliszczynski, Maciej J ^a   Bao, Jing Q ^a   Day, Jeffrey S ^a   Higgins, J William ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CANNULATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG KIDNEY LEVEL; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; DRUG TRANSPORT; ENTEROHEPATIC CIRCULATION; KIDNEY PARENCHYMA; LIVER PERFUSION; LIVER SINUSOID; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BILE; BILE DUCTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; KIDNEY; LIVER; MALE; METFORMIN; MICE; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84886468704     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053025     Document Type: Article

References (22)

1. Choi MK, Jin QR, Jin HE, Shim CK, Cho DY, Shin JG, and Song IS (2007) Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin. Biopharm Drug Dispos 28:501-510.
2. Chou CH (2000) Uptake and dispersion of metformin in the isolated perfused rat liver. J Pharm Pharmacol 52:1011-1016.
3. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
4. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236. Glucophage (2009) Prescribing information. Bristol-Meyers Squibb Company, New York.
5. Gong L, Goswami S, Giacomini KM, Altman RB, and Klein TE (2012) Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 22:820-827.
6. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, and Kirkpatrick CM, et al. (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81-98.
7. Higgins JW, Bedwell DW, and Zamek-Gliszczynski MJ (2012) Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos 40:1170-1177.
8. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K, Kondo T, Yuasa H, Nakayama H, and Horita S, et al. (2010) Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 333:341-350.
9. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, and Inui K (2005) Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20:379-386.
10. Maeda T, Oyabu M, Yotsumoto T, Higashi R, Nagata K, Yamazoe Y, and Tamai I (2007) Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Oct1 in rats. Drug Metab Dispos 35:1580-1586.
11. Nishimura M and Naito S (2005) Tissue-specific mRNA expression profiles of human ATPbinding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20: 452-477.
12. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, and Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 102:17923-17928.
13. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, and Burchard EG, et al. (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422-1431.
14. Stepensky D, Friedman M, Raz I, and Hoffman A (2002) Pharmacokinetic- pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos 30:861-868.
15. Stepensky D, Friedman M, Srour W, Raz I, and Hoffman A (2001) Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. J Control Release 71:107-115.
16. Stocker SL, Morrissey KM, Yee SW, Castro RA, Xu L, Dahlin A, Ramirez AH, Roden DM, Wilke RA, and McCarty CA, et al. (2013) The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther 93:186-194.
17. Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, and Inui K (2009) Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 75:1280-1286.
18. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, and Woods HF (1981) Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 12:235-246.
19. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, and Sugiyama Y (2002) Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302:510-515.
20. Zamek-Gliszczynski MJ, Day JS, Hillgren KM, and Phillips DL (2011) Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics. Drug Metab Dispos 39:1794-1800.
21. Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, Giacomini KM, and Hillgren KM (2012) Highlights from the International Transporter Consortium second workshop. Clin Pharmacol Ther 92:553-556.
22. Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, and Brouwer KL (2009) Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab Dispos 37:386-390.